

HENRY FORD HEALTH INSTITUTIONAL BIOSAFETY COMMITTEE (IBC) MEETING



Board Meetings: Quarterly
Quorum = 5

Friday, March 20, 2026

MEMBER ATTENDANCE:

PRESENT	ABSENT	MEMBER NAME	DEGREE EARNED	AREA OF SPECIALTY	DEPARTMENT	AFFILIATE OF HFH?
V		Wilson, George (C)	PhD	Biomedical/Radiobiology	Research Administration	Yes
V		Palanisamy, Nallasivam (VC)	PhD	Genomics Technology	Urology	Yes
V		Baker, Kevin C.	PhD	Animals	Bone and Joint	Yes
V		Bobbitt, Kevin	PhD	Viral Immunology	Public Health Services	Yes
V		Hay, Nancy	MHSA	Community Interest	Non-Affiliated	No
V		Liu, Xianshuang	PhD	Gene Therapy	Neurology	Yes
V		Notebaert, Andrea	BS	Animals	Bioresources	Yes
	X	Nyati, Shyam	PhD	Gene Therapy	Radiation Oncology	Yes
	X	Ramesh, Mayur	MD	Human Clinical Trials	Infectious Disease	Yes
V		Swiecki, Mark	BS	Community Interest	Non-Affiliated	No

IBC Quorum Rules: The National Institutes of Health (NIH) Guidelines, which govern recombinant and synthetic nucleic acid research, do not explicitly define a quorum for an IBC; however, HFH IBC considers a quorum to be a majority of the total voting membership (50% of the membership for the year plus one).

CONSULTANTS/INVITED GUESTS:

PRESENT	NAME	DEGREE/S EARNED	ROLE	AFFILIATED W/ HFH?
	Combs, Lena	BS, MJ	Research Administration	Yes
	Eliya, Sonia	PharmD	Research Pharmacy	Yes
	Pabla, Pardeep	PharmD	Research Pharmacy	Yes
V	Raju, Vivek	MS	Research Administration	Yes
	Trancik, Emily	PhD	Ethics	Yes
	White, Mary Jo	MBA	Compliance	Yes
V	Hughes, Jennifer	BS	Research Administration	Yes

Others Present may include regularly attending consultants, IBC administrative staff and representatives of the HFH Office of General Counsel. Consultants/Staff are not members of the IBC and shall not vote. However, they must disclose any conflicts of interest. During this meeting, staff or consultants may be called upon to provide advice or counsel to the IBC concerning study activities.

Presiding: George Wilson, Ph.D., Chair

Recording: Minutes for this meeting were recorded by Jennifer Hughes, Senior Coordinator of Research Compliance.

1.0 CHANGES TO IBC MEETING MINUTES

Structure of the meeting minutes have changed to follow NIH Guideline updates. The new focus is on redacting details of the study team. The Guidelines do not focus on the IBC members. To align with the Institutional Review Board (IRB) template change IBC will remove names of members from discussion sections of the meeting minutes. This will make the public meeting minutes more anonymous and protect our members.

2.0 GENERAL INFORMATION

2.1. QUORUM AND CALL TO ORDER

The Chair of the meeting verified that quorum requirements were met. The meeting was called to order at 2:00 PM with 8 of 10 members present. The meeting was conducted via video conferencing, and it was confirmed that all present members were able to participate in the discussion. All IBC members and consultants received access to all pertinent materials for review prior to the meeting.

2.2. REVIEW OF PREVIOUS MEETING MINUTES

The meeting minutes from the previous IBC meeting on January 16, 2026 were provided to all the attendees prior to the meeting for review. The minutes were voted on and approved by the committee.

APPROVED: Minutes were approved				
TOTAL MEMBERS VOTING	# FOR	# AGAINST	# ABSTAINED	# RECUSAL(S)
8	8	0	0	0

3.0 REVIEW OF PROTOCOLS

Event Type	Agenda #	Reviewers	PI	Protocol #	Protocol Title:
New Protocol Application	3.1	Liu, Xianshuang, PhD <i>Primary</i>		IBC 2026.04	Epigenetic Control of Langerhans Cells and Dendritic Epidermal T Cells by miRNAs and Histone mediated Modifications
		Notebaert, Andrea, LVT <i>Secondary</i>			
		Swiecki, Mark, BS <i>Non-Affiliated Reviewer</i>			

PURPOSE: The specific aims of this project are: (1) to define the roles of selected miRNAs and histone regulators in the development and homeostasis of epidermal immune cells, including Langerhans cells and Dendritic Epidermal T Cells; (2) to determine how these pathways regulate LC and DETC effector functions during skin inflammation and infection; and (3) to delineate the molecular mechanisms underlying these regulatory pathways to identify potential therapeutic targets.

Training: Complete for all study members listed.

RG2, NIH Section III-E

REVIEWER PRESENTATION AND DISCUSSION:

- Scientific member provided an overview of the submission.
- How to harvest, culture, and test are in the SOP.
- Scientific member motioned to withhold pending response to the requested changes.

ACTION TAKEN BY IBC: Withhold. The IBC action was taken pursuant to a motion made by the reviewer of this study which was seconded by another IBC Committee member:

Withhold Approval: The protocol will need to be resubmitted with the following requested changes to be reviewed via expedited procedures by a Committee member:

- More information needed on exposure risk in section 3B.
 - Safety risks for personnel working with toxins.
- In section 10 define type and class for equipment.
 - Do the centrifuges have sealed rotors? Do not want aerosols created.
- In section 5a the product number for the type of Tamoxifen (TAM) to be purchased was not added.
 - How will the TAM be prepared?
 - What solvent will be used?
- Update funding details.
- Is radiation being done with the bone marrow? Are viral vectors going to be used with the bone marrow?

TOTAL MEMBERS VOTING	# FOR	# AGAINST	# ABSTAINED	# RECUSAL(S)
8	8	0	0	0

4.0 ROUNDTABLE DISCUSSION

4.1 Research was done with MRSA that was not approved by IBC.

- MRSA is Risk Group 2.
- Came to IRB's attention because the Principal Investigator (PI) wanted to publish.
- In vitro work.
- Under review with Research Compliance.
- Chair has written information for the next Research Compliance Newsletter to inform PIs when IBC approval is needed.
 - Can the Research Safety Committee (RSC) assist in this endeavor?

4.2 We approve renewals and amendments that are reviewed and approved by the Chair. Should IBC be provided this information?

- Yes

4.3 IRB linked protocols will be on-line in IRB Manager.

4.4 Share with the IBC members the tracking for IBC protocols.

5.0 MEETING ADJOURNMENT

The meeting was adjourned at 2:39 pm.

Meeting minutes respectfully submitted by Jennifer Hughes, BS.